Creatv MicroTech Receives DoD Funding for Lung Cancer Screening
ROCKVILLE, MD, September 14, 2018 Creatv MicroTech, Inc. (Creatv) has received a $625,000 award from the Department of Defense Congressionally Directed Medical Research Programs (CDMRP) to investigate their discovery of giant circulating cells found in peripheral blood for non-invasive detection of lung cancer by differentiating malignant from benign pulmonary nodules detected by low dose CT (LDCT). In the three-year study, Creatv will examine blood samples from 1,250 subjects at high risk for lung cancer based on their smoking history and occupational exposure to carcinogens. The research will be carried out in collaboration with Fox Chase Cancer Center (FCCC) and the Philadelphia VA Hospital.
Lung cancer remains the leading cause of cancer death in the United States, with 234,000 new cases and 154,000 deaths expected in 2018. Disease that is found and treated early has a higher probability of patient survival indicating that screening has a crucial role in saving lives.
Low dose CT is recommended for lung cancer screening for 8 million smokers by the US Preventative Services Task Force, however, there are several problems with the current screening paradigm. Most critically, over 39% of screened subjects were determined to have “indeterminate” pulmonary nodules with a 96.4% false positive rate which leads to many costly, risky, and possibly unnecessary biopsies.
Creatv has identified a previously unanalyzed cancer associated circulating biomarker which appears as polynucleated giant cell (25 to 300 microns in size) found in the blood of cancer patients but absent in healthy controls. Creatv named these cells Cancer Associated Macrophage-like Cells (CAMLs) and have preliminary shown that CAMLs are found in high percentages in all stages of cancer, even in Stage I, and present in most major solid cancers.
About Creatv MicroTech Creatv MicroTech (www.creatvmicrotech.com) is a privately held company founded in 2000. Creatv’s expertise in biodetection and microfabrication were instrumental in the development of its CellSieve™ microfiltration platform and the discovery of the CAML biomarker. CellSieve™ assays are available for research use only, currently being tested in hospitals and clinics throughout the US, and nine other countries. Creatv has been recognized by an R&D 100 Award, inclusion on the Micro/Nano 25-Technologies of Tomorrow List, and Montgomery County Maryland's Bioscience Company of the Year Award.
The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014 is the awarding and administering office.
Contact: Cha-Mei Tang, Sc.D. Founder, President and CEO, Creatv MicroTech, Inc. 240-441-3311 email@example.com
SOURCE Creatv MicroTech